T cell exclusion, immune privilege, and the tumor microenvironment
暂无分享,去创建一个
[1] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[2] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[3] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[4] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[5] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[6] Sebastian Amigorena,et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.
[7] Vivien W. Chan,et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.
[8] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[9] G. Cline,et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.
[10] G. Wahl,et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.
[11] S. Goerdt,et al. Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.
[12] L. Coussens,et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.
[13] T. Matozaki,et al. The CD47-SIRPα signalling system: its physiological roles and therapeutic application. , 2014, Journal of biochemistry.
[14] P. Dessen,et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.
[15] G. Coukos,et al. Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.
[16] L. Tran,et al. Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression , 2014, Molecular and Cellular Biology.
[17] J. C. Love,et al. In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.
[18] L. Zitvogel,et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. , 2014, Cancer research.
[19] R. Weichselbaum,et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. , 2014, Cancer cell.
[20] Eric C. Sorenson,et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization , 2013, The Journal of experimental medicine.
[21] L. Coussens,et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells , 2013, Oncoimmunology.
[22] T. Okazaki,et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.
[23] Derek S. Chan,et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.
[24] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2014 .
[25] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[26] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[27] Masashi Kato,et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells , 2013, Proceedings of the National Academy of Sciences.
[28] Jens-Peter Volkmer,et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.
[29] J. Wolchok,et al. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.
[30] James O. Jones,et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia , 2013, The Journal of experimental medicine.
[31] Huidong Shi,et al. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. , 2013, Immunity.
[32] Dai Fukumura,et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. , 2013, Cancer research.
[33] G. Freeman,et al. Strength of PD-1 signaling differentially affects T-cell effector functions , 2013, Proceedings of the National Academy of Sciences.
[34] D. Munn,et al. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.
[35] Sunil Singhal,et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery , 2012, Proceedings of the National Academy of Sciences.
[36] W. Wick,et al. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.
[37] R. Jain,et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[38] G. Prendergast,et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.
[39] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[40] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[41] D. Bar-Sagi,et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.
[42] N. Jhala,et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.
[43] L. Ellis,et al. Antiangiogenic therapy—evolving view based on clinical trial results , 2012, Nature Reviews Clinical Oncology.
[44] C. Payne,et al. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[45] A. Rudensky,et al. Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.
[46] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[47] A. Corti,et al. Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy , 2012, The Journal of Immunology.
[48] Pierre Validire,et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. , 2012, The Journal of clinical investigation.
[49] J. Wolchok,et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. , 2011, Cancer research.
[50] L. Lazzarato,et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells , 2011, The Journal of experimental medicine.
[51] Karin Jirström,et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.
[52] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[53] Drew A. Torigian,et al. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.
[54] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[55] James O. Jones,et al. Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .
[56] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[57] Douglas B. Evans,et al. High Levels of Expression of Human Stromal Cell–Derived Factor-1 Are Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[58] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[59] V. Engelhard,et al. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors , 2010, The Journal of experimental medicine.
[60] S. Rosenberg,et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.
[61] V. Reuter,et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas , 2010, Modern Pathology.
[62] J. Abastado,et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. , 2010, The Journal of clinical investigation.
[63] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[64] S. Hirohashi,et al. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. , 2009, American journal of clinical pathology.
[65] E. Unanue,et al. Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.
[66] Fabian Kiessling,et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.
[67] P. Gimotty,et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.
[68] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[69] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[70] S. Steinberg,et al. Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma , 2005, The Journal of Immunology.
[71] H. Ohtani,et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis , 2004, British Journal of Cancer.
[72] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[73] Gordon Stamp,et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.
[74] D. Scadden,et al. Active movement of T cells away from a chemokine , 2000, Nature Medicine.
[75] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[76] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[77] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[78] S. Riddell,et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.
[79] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[80] G. Klein,et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.
[81] P. Medawar. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.
[82] P. Rous,et al. ON THE CAUSE OF THE LOCALIZATION OF SECONDARY TUMORS AT POINTS OF INJURY , 1914, The Journal of experimental medicine.